WeVote
Log In

Bill

Bill

HB 5589

AN ACT CONCERNING HEALTH INSURANCE COVERAGE FOR PAXLOVID.

2025 Regular Session Introduced by Nick Menapace

Connecticut bill mandates health insurers cover antiviral Paxlovid without patient cost-sharing to improve access for COVID-19 treatment.

REF. TO JOINT COMM. ON Insurance and Real Estate
#healthinsurance
0
WeVote Research Nonpartisan
Bill Summary · HB 5589

Legislative bill overview

HB 5589 would require health insurance plans in Connecticut to cover Paxlovid (an antiviral COVID-19 treatment) without cost-sharing barriers such as copayments, coinsurance, or deductibles. The bill aims to ensure equitable access to this medication regardless of a patient's ability to pay out-of-pocket expenses.

Why is this important

Paxlovid significantly reduces severe illness and hospitalization risk when taken early in COVID-19 infection, particularly for vulnerable populations. Removing financial barriers could increase treatment uptake among those who need it most and reduce overall healthcare costs associated with preventable COVID complications.

Potential points of contention

  • Insurance cost impact: Insurers may argue that mandated coverage without cost-sharing increases premiums for all enrollees, potentially raising overall healthcare costs
  • Medication access equity: Debate over whether this sets a precedent requiring zero-cost coverage for other prescription medications, or if Paxlovid merits unique treatment
  • Clinical appropriateness: Questions about whether blanket coverage without medical necessity gatekeeping could lead to inappropriate use or resistance concerns over long-term antiviral deployment
  • Federal coverage status: Potential overlap or conflict with existing federal COVID treatment programs and pricing agreements that may already subsidize Paxlovid

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.